Ready-to-use Biosimilar Cell Lines

UGA Biopharma GmbH offers to their clients so called Ready-to-use Biosimilar Cell Lines. This are in-house developed CHO cell lines stably expressing different biosimilar molecules, that are instantly available for in-licensing. The client profits, because the cell lines are directly available, and development data including titer and quality attributes are promptly accessible.

Dossiers, shortly summarizing the development and the associated available quality and titer data of each Ready-to-use Biosimilar Cell Line are available for all cell lines listed below.

Ready-to-use Biosimilar Cell Lines including lab scale USP and DSP


Adalimumab Biosimilar (limited use only*)           

Full package ready for sales now: 

Research Cell Bank (RCB) including safety testing 

Optimized fermentation process (USP) 

Optimized downstream purification process (DSP) and analytics 

Including proof of activity of the expressed protein 



If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

 

Bevacizumab Biosimilar (limited use only*)           

Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.


If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

 

Mepolizumab Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

 

Nivolumab Biosimilar (limited use only*)           
A product concentration over 3 g/L has been obtained during a Nivolumab consistency run in stirred bioreactors.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Omalizumab Biosimilar (limited use only*)           
A product concentration of 3 g/L has been obtained during the Omalizumab biosimilar development project.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Trastuzumab Biosimilar (limited use only*)           

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.   

Under Development

Those cell lines are currently under development at UGA Biopharma.

Alglucosidase alpha Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.   
Efmoroctocog alfa Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.   
Elosulfase Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Galsulfase Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Infliximab Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.   

Former Projects

Those cell lines were developed by UGA but are currently not available as Ready-to-use Biosimilar Cell Lines.

UGA has already gained a lot of experience with the molecules listed below. Furthermore, the costs to develop those projects for the client are reduced, because several methods, like e.g. DSP or analytical methods, were already established in-house.

These biosimilar expressing cell lines are perfect for clients that want to profit from our long-standing experience. The client can get a cell line with a reliable high titer from 4 to 7 g/L (for easy to express mAb) in a very short development timeline. Even lower development costs are guaranteed.

Aflibercept Biosimilar (limited use only*)           

Aflibercept is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.


If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Please you consider the disclaimer on this website.

 

Alirocumab Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Anakinra Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Certolizumab Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Darbepoetin alfa Biosimilar (limited use only*)           

Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the originator.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Dulaglutide Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Dupilumab Biosimilar (limited use only*)           
An outstanding product concentration higher than 7 g/L could be reached during the Dupilumab development project! The first CHOice® Medium works very well for Dupilumab clones.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Eculizumab Biosimilar (limited use only*)           

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Erenumab Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Etanercept Biosimilar (limited use only*)           

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Glycoprotein E Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.   
Idursulfase Biosimilar (limited use only*)           
This biosimilar project is under development at UGA Biopharma GmbH.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.   
Ipilimumab Biosimilar (limited use only*)           
Typical charge profil of ther reference medical product of Ipilimumab.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Natalizumab Biosimilar (limited use only*)           
The primary structure of a biosimilar has to be identical to the originator molecule. The result of the peptide mapping of the Natalizumab biosimilar is depicted here.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Panitumumab Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
 
Pembrolizumab Biosimilar (limited use only*)           
Pembrolizumab (IgG4) biosimilar development project has been finalized in a very short time line – according to the High Speed Workflow of UGA Biopharma!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.

Pertuzumab Biosimilar (limited use only*)           
Outstanding productivity higher than 5 g/L reached during the pertuzumab development project!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Secukinumab Biosimilar (limited use only*)           
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.   

New Cell line development

Moreover, UGA wants to highlight that all cell lines listed above, can also be developed as NEW cell lines.

If you are interested in a molecule or biosimilar that is not listed here, please also contact us under info@ugabiopharma.com and we will discuss your upcoming project with you. We will be glad to provide you with an individual project proposal and attractive quotation.

UGA has experience with all major protein classes: monoclonal antibodies (mAbs, IgG1 and IgG4), bispecific antibodies, chimeric antibodies, humanized antibodies, fusion proteins, enzymes, hormones, and EPO derivates.

Disclaimer

*Limited use only: Until the expiration of the patent and potential supplementary protection certificates related to the reference medical product the client must not (i) produce, offer or put on the market the respective medical product or possess the product for such purposes, or (ii) use the cell lines or products offered by UGA Biopharma except for experimental use or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act.           




Back to products and services


Contact

UGA Biopharma GmbH
Neuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail:  info@ugabiopharma.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49(0)3302 / 2024900